RESEARCH

Publication List in Chronological Order

Sort by Year Subject Author

Jump to: 2011 2009 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 Pre-1994

2011

Wheeler DW, Thompson AJ, Corletto F, Reckless J, Loke JCT, Lapaque N, Grant AJ, Mastroeni P, Grainger DJ, Padgett CL, OÕBrian JA, Miller NGA, Trowsdale J, Lummis SCR, Menon DK, Beech JS. Anaesthetic Impairment of Immune Function Is Mediated via GABAA Receptors. PLoS ONE, 2011, 6(2): e17152.
Read the document

Bourne GL, Grainger DJ. Development and characterisation of an assay for furin activity. J Immunol Methods. 2011; 364:101-8
Read the document

2007

Beech JS, Wheeler DW, Reckless J, Grant AJ, Price J, Mastroeni P, Grainger DJ, Menon DK. The MHP36 line of murine neural stem cells expresses functional CXCR1 chemokine receptors that initiate chemotaxis in vitro. J Neuroimmunol. 2007;184:198-208.

Grainger DJ. TGF-beta and atherosclerosis in man. Cardiovasc Res. 2007;74:213-22.
Read the document

2006

Mosedale DE, Chauhan A, Schofield PM, Grainger DJ. A pattern of anti-carbohydrate antibody responses present in patients with advanced atherosclerosis. J Immunol Methods. 2006;309:182-91

Underwood BR, Broadhurst D, Dunn WB, Ellis DI, Michell AW, Vacher C, Mosedale DE, Kell DB, Barker RA, Grainger DJ, Rubinsztein DC. Huntington disease patients and transgenic mice have similar pro-catabolic serum metabolite profiles. Brain. 2006;129:877-86

Grainger DJ. Metabolic profiling in heart disease. Heart Metabolism. 2006;32:22-25.
Read the document

Griffiths SL, Grainger DJ. Proposal of a novel diabetogenic mechanism involving the serpin PAI-1. Bioessays. 2006;28:629-41

Mosedale DE, Sandhu MS, Luan J, Goodall M, Grainger DJ. A new sensitive and specific enzyme-linked immunosorbent assay for IgD. J Immunol Methods. 2006;313:74-80.

2005

Fox DJ, Reckless J, Wilbert SM, Greig I, Warren S, Grainger DJ. Identification of 3-(Acylamino)azepan-2-ones as Stable Broad-Spectrum Chemokine Inhibitors Resistant to Metabolism in Vivo. J Med Chem. 2005;48:867-874.

Grainger DJ, Lever AM. Blockade of chemokine-induced signalling inhibits CCR5-dependent HIV infection in vitro without blocking gp120/CCR5 interaction. Retrovirology. 2005;2:23.

Mosedale DE, Smith DJ, Aitken S, Schofield PM, Clarke SC, McNab D, Goddard H, Gale CR, Martyn CN, Bethell HW, Barnard C, Hayns S, Nugent C, Panicker A, Grainger DJ. Circulating levels of MCP-1 and eotaxin are not associated with presence of atherosclerosis or previous myocardial infarction. Atherosclerosis. 2005;183:268-74

Reckless J, Tatalick L, Wilbert S, McKilligin E, Grainger DJ. Broad-spectrum chemokine inhibition reduces vascular macrophage accumulation and collagenolysis consistent with plaque stabilization in mice. J Vasc Res. 2005;42:492-502

Schroff RW, Touvay C, Culler MD, Dong JZ, Taylor JE, Thurieau C, McKilligin E. The toxicology of chemokine inhibition. Mini Rev Med Chem. 2005;5:849-55

Grainger DJ, Reckless J, Fox DJ. Broad spectrum chemokine inhibitors related to NR58-3.14.3. Mini Rev Med Chem. 2005;5:825-32

Grainger DJ, Schofield PM. Tamoxifen for the prevention of myocardial infarction in humans: preclinical and early clinical evidence. Circulation. 2005;112:3018-24

2004

Grainger DJ. Transforming growth factor beta and atherosclerosis: so far, so good for the protective cytokine hypothesis. Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):399-404.

Frow EK, Reckless J, Grainger DJ. Tools for anti-inflammatory drug design: In vitro models of leukocyte migration. Med Res Rev. 2004 May;24(3):276-98.

Grainger DJ, Aitken S. A microtitre format assay for proline in human serum or plasma. Clin Chim Acta. 2004; 343:113-8.

Grainger DJ, Reckless J, McKilligin E. Apolipoprotein E modulates clearance of apoptotic bodies in vitro and in vivo, resulting in a systemic proinflammatory state in apolipoprotein E-deficient mice. J Immunol. 2004;173:6366-6375.

2003

Naidu BV, Farivar AS, Krishnadasan B, Woolley SM, Grainger DJ, Verrier ED, Mulligan MS. Broad-spectrum chemokine inhibition ameliorates experimental obliterative bronchiolitis. Ann Thorac Surg 2003 Apr;75(4):1118-1122

Grainger DJ, Reckless J. Broad-spectrum chemokine inhibitors (BSCIs) and their anti-inflammatory effects in vivo. Biochem Pharmacol. 2003; 65:1027-1034.

Brindle JT, Nicholson JK, Schofield PM, Grainger DJ, Holmes E. Application of chemometrics to proton-NMR spectroscopic data to investigate a relationship between human serum metabolic profiles and hypertension. Analyst 2003; 128:32-36

2002

Sanders TA, Dean TS, Grainger D, Miller GJ, Wiseman H. Moderate intakes of intact soy protein rich in isoflavones compared with ethanol-extracted soy protein increase HDL but do not influence transforming growth factor beta(1) concentrations and hemostatic risk factors for coronary heart disease in healthy subjects. Am J Clin Nutr. 2002;76:373-377.

Fox DJ, Reckless J, Warren SG, Grainger DJ. Design, synthesis and preliminary pharmacological evaluation of N-alkyl 3-aminoglutarimides as broad-spectrum chemokine inhibitors in vitro and anti-inflammatory agents in vivo. J Med Chem. 2002; 45:360-370.

Grainger D, Bethell HWL. High titres of serum anti-nuclear antibodies, mostly directed against nucleolar antigens, are associated with the presence of coronary atherosclerosis. Annals of Rheumatic Diseases 2002; 61:110-114.

Brindle J, Antti H, Holmes E, Tranter G, Nicholson JK, Bethell HWL, Clarke S, Schofield PM, McKilligin E, Mosedale D, Grainger DJ. Rapid and non-invasive diagnosis of the presence and severity of coronary heart disease using 1H-NMR based metabonomics. Nature Med. 2002; 8:1439-1445.

2001

McDowell N, Gurdon JB, Grainger DJ. Formation of a functional morphogen gradient by a passive process in tissue from the early Xenopus embryo. Int J Dev Biol. 2001;45:1-9.

Grainger DJ, McWilliam NA, Baglin TP, Byrne CD. Suppressing thrombin generation is compatible with the development of atherosclerosis in mice. Thrombosis Res. 2001; 102:71-80.

Grainger DJ. Human gene therapy: are we still expecting too much, too soon? Quarterly J Med. 2001; 94:337-339. Editorial.

McKilligin E, Grainger DJ. Cell volume and rate of proliferation, but not protein expression pattern distinguish pup/intimal smooth muscle cells from subcultured adult smooth muscle cells. Cell Proliferation 2001; 34: 275-292.

Reckless J, Tatalick LM, Grainger DJ. The pan-chemokine inhibitor NR58-3.14.3 abolishes TNF-alpha accumulation and leukocyte recruitment induced by lipopolysaccharide in vivo. Immunology 2001; 103:244-254.

Reckless J, Rubin EM, Verstuft JB, Metcalfe JC, Grainger DJ. A common phenotype associated with atherogenesis in diverse mouse models of vascular lipid lesions. J Vasc Res. 2001; 38:256-265.

Beech JS, Reckless J, Mosedale DE, Grainger DJ, Williams SCR, Menon DK. Neuroprotection in ischemia-reperfusion injury: an anti-inflammatory approach using a novel broad spectrum chemokine inhibitor. J Cerebral Blood Flow Metabolism. 2001; 21:683-689.

2000

Grainger DJ, Mosedale DE. TGF-beta and the cardiovascular system. In Progress in inflammation research : TGF-beta. (Editors : S.M. Wahl & S. Breit). Elsevier. pp 91-147.

Wilbert SM, Engrissei G, Yau EK, Grainger DJ, Tatalick L, Axworthy DB. Quantitative analysis of a synthetic peptide, NR58-3.14.3, in serum by LC-MS with inclusion of a diastereomer as internal standard. Anal Biochem. 2000 Feb 1;278(1):14-21.

Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine Growth Factor Rev. 2000 Mar-Jun;11(1-2):133-45.

Grainger DJ. A votre santŽ? Lancet 2000;356:92. Commentary.

Grainger DJ, Frow EK. Thrombospondin-1 does not activate TGF-beta1 in a chemically defined system or in smooth muscle cell cultures. Biochem. J. 2000;350: 291-298.

Grainger DJ, Mosedale DE, Metcalfe JC, Bottinger EP. Dietary fat and reduced levels of TGFbeta1 act synergistically to promote activation of the vascular endothelium and formation of lipid lesions. J Cell Sci. 2000;113(Pt 13):2355-2361.

1999

Reckless J, Grainger DJ. Identification of oligopeptide sequences which inhibit migration induced by a wide range of chemokines. Biochem J. 1999 Jun 15;340 ( Pt 3):803-11.

Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD. Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet. 1999 Jan;8(1):93-7.

Reckless J, Rubin EM, Verstuyft JB, Metcalfe JC, Grainger DJ. Monocyte chemoattractant protein-1 but not tumor necrosis factor-alpha is correlated with monocyte infiltration in mouse lipid lesions. Circulation. 1999 May 4;99(17):2310-6.

Mosedale DE, Grainger DJ. An antibody present in normal human serum inhibits the binding of cytokines to their receptors in an in vitro system. Biochem J. 1999 Oct 1;343 Pt 1:125-33.

Grainger DJ, Percival J, Chiano M, Spector TD. The role of serum TGF-beta isoforms as potential markers of osteoporosis. Osteoporos Int. 1999;9(5):398-404.

1998

Syrris P, Carter ND, Metcalfe JC, Kemp PR, Grainger DJ, Kaski JC, Crossman DC, Francis SE, Gunn J, Jeffery S, Heathcote K. Transforming growth factor-beta1 gene polymorphisms and coronary artery disease. Clin Sci (Colch). 1998 Dec;95(6):659-67. [discussed in Commentary Clin. Sci 1998 Dec;95(6):645-6].

Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Grainger DJ. Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels. Atherosclerosis. 1998 Sep;140(1):45-53.

Grainger DJ, Reckless J, Metcalfe JC, Hughes SD, Rubin EM, Lawn, RM. Lipoprotein(a) and the endothelium: a feedback loop in atherosclerosis. In Atherosclerosis XI (Editors : D. MathŽ & J.-C. Fruchart). Elsevier. 551-7.

Grainger DJ, Metcalfe JC. TGF-beta and cardiovascular protection. In The endothelium in clinical practice. (Editors: G.M. Rubanyi & V.J. Dzau). Marcel-Dekker. 203-43.

Grainger DJ, Metcalfe JC, Grace AA, Mosedale DE. Transforming growth factor-beta dynamically regulates vascular smooth muscle differentiation in vivo. J Cell Sci. 1998 Oct;111 (Pt 19):2977-88.

Grainger DJ, Metcalfe JC, Byrne CD. Changing views on plasma risk factors for atherosclerosis. J. Irish Coll. Phys. Surg. 1999 Jan;28(1):32-7.

1997

Reckless J, Metcalfe JC, Grainger DJ. Tamoxifen decreases cholesterol sevenfold and abolishes lipid lesion development in apolipoprotein E knockout mice. Circulation. 1997 Mar 18;95(6):1542-8.

Hughes SD, Lou XJ, Ighani S, Verstuyft J, Grainger DJ, Lawn RM, Rubin EM. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest. 1997 Sep 15;100(6):1493-500.

Grainger DJ, Byrne CD, Witchell CM, Metcalfe JC. Transforming growth factor beta is sequestered into an inactive pool by lipoproteins. J Lipid Res. 1997 Nov;38(11):2344-52.

1996

Lawn RM, Pearle AD, Kunz LL, Rubin EM, Reckless J, Metcalfe JC, Grainger DJ. Feedback mechanism of focal vascular lesion formation in transgenic apolipoprotein(a) mice. J Biol Chem. 1996 Dec 6;271(49):31367-71.

Mosedale DE, Metcalfe JC, Grainger DJ. Optimization of immunofluorescence methods by quantitative image analysis. J Histochem Cytochem. 1996 Sep;44(9):1043-50.

Kirschenlohr HL, Metcalfe JC, Grainger DJ. Cultures of proliferating vascular smooth muscle cells from adult aorta. In Human cell culture. Humana Press. 113-27

Grainger DJ, Metcalfe JC. Tamoxifen: teaching an old drug new tricks? Nat Med. 1996 Apr;2(4):381-5. Review.

1995

Grainger DJ, Metcalfe JC. A pivotal role for TGF-beta in atherogenesis? Biol Rev Camb Philos Soc. 1995 Nov;70(4):571-96.

Grainger DJ, Witchell CM, Metcalfe JC. Tamoxifen elevates transforming growth factor-beta and suppresses diet-induced formation of lipid lesions in mouse aorta. Nat Med. 1995 Oct;1(10):1067-73. [discussed in News and Views Nat Med. 1995 Oct;1(10):1000-2.]¤

Grainger DJ, Wakefield L, Bethell HW, Farndale RW, Metcalfe JC. Release and activation of platelet latent TGF-beta in blood clots during dissolution with plasmin. Nat Med. 1995 Sep;1(9):932-7.

Kemp PR, Metcalfe JC, Grainger DJ. ID - a dominant negative regulator of skeletal muscle differentiation -is not involved in maturation or differentiation of vascular smooth muscle cells. FEBS Letters 1995; 368:81-86.

Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Proliferation of human aortic vascular smooth muscle cells in culture is modulated by active TGF beta. Cardiovasc Res. 1995 Jun;29(6):848-55.

Metcalfe JC, Grainger DJ. Transforming growth factor-beta and the protection from cardiovascular injury hypothesis. Biochem Soc Trans. 1995 May;23(2):403-6.

Grainger DJ, Metcalfe JC. Transforming growth factor-beta: the key to understanding lipoprotein(a)? Curr Opin Lipidol. 1995 Apr;6(2):81-5.

Kemp PR, Osbourn JK, Grainger DJ, Metcalfe JC. Cloning and analysis of the promoter region of the rat SM22 alpha gene. Biochem J. 1995 Sep 15;310 (Pt 3):1037-43.

Metcalfe JC, Grainger DJ. TGF-beta: implications for human vascular disease. J Hum Hypertens. 1995 Aug;9(8):679.

Grainger DJ, Kemp PR, Metcalfe JC, Liu AC, Lawn RM, Williams NR, Grace AA, Schofield PM, Chauhan A. The serum concentration of active transforming growth factor-beta is severely depressed in advanced atherosclerosis. Nat Med. 1995 Jan;1(1):74-9. [discussed in News and Views Nat Med. 1995 Jan;1(1):22-3.]

Grainger DJ, Mosedale DE, Metcalfe JC, Weissberg PL, Kemp PR. Active and acid-activatable TGF-beta in human sera, platelets and plasma. Clin Chim Acta. 1995 Feb 28;235(1):11-31.

1994

Grainger DJ, Witchell CM, Weissberg PL, Metcalfe JC. Mitogens for adult rat aortic vascular smooth muscle cells in serum-free primary culture. Cardiovasc Res. 1994 Aug;28(8):1238-42.

Grainger DJ, Kemp PR, Witchell CM, Weissberg PL, Metcalfe JC. Transforming growth factor beta decreases the rate of proliferation of rat vascular smooth muscle cells by extending the G2 phase of the cell cycle and delays the rise in cyclic AMP before entry into M phase. Biochem J. 1994 Apr 1;299 ( Pt 1):227-35.

Grainger DJ, Kemp PR, Liu AC, Lawn RM, Metcalfe JC. Activation of transforming growth factor-beta is inhibited in transgenic apolipoprotein(a) mice. Nature. 1994 Aug 11;370(6489):460-2.

Pre-1994

Grainger DJ, Hesketh TR, Weissberg PL, Metcalfe JC. Hexamethylenebisacetamide selectively inhibits the proliferation of human and rat vascular smooth-muscle cells. Biochem J. 1992 Apr 15;283 ( Pt 2):403-8.

Grainger DJ, Hesketh TR, Metcalfe JC, Weissberg PL. A large accumulation of non-muscle myosin occurs at first entry into M phase in rat vascular smooth-muscle cells. Biochem J. 1991 Jul 1;277 ( Pt 1):145-51.

Kemp PR, Grainger DJ, Shanahan CM, Weissberg PL, Metcalfe JC. The Id gene is activated by serum but is not required for de-differentiation in rat vascular smooth muscle cells. Biochem J. 1991 Jul 1;277 (Pt 1):285-8

Grainger DJ, Kirschenlohr HL, Metcalfe JC, Weissberg PL, Wade DP, Lawn RM. Proliferation of human smooth muscle cells promoted by lipoprotein(a). Science. 1993 Jun 11;260(5114):1655-8.

Weissberg PL, Grainger DJ, Shanahan CM, Metcalfe JC. Approaches to the development of selective inhibitors of vascular smooth muscle cell proliferation. Cardiovasc Res. 1993 Jul;27(7):1191-8.

Kirschenlohr HL, Metcalfe JC, Weissberg PL, Grainger DJ. Adult human aortic smooth muscle cells in culture produce active TGF-beta. Am J Physiol. 1993 Aug;265(2 Pt 1):C571-6.

Grainger DJ, Weissberg PL, Metcalfe JC. Tamoxifen decreases the rate of proliferation of rat vascular smooth-muscle cells in culture by inducing production of transforming growth factor beta. Biochem J. 1993 Aug 15;294 ( Pt 1):109-12.

Grainger DJ, Witchell CM, Watson JV, Metcalfe JC, Weissberg PL. Heparin decreases the rate of proliferation of rat vascular smooth muscle cells by releasing transforming growth factor beta-like activity from serum. Cardiovasc Res. 1993 Dec;27(12):2238-47.